Stifel Nicolaus Upgrades Vor Biopharma (NYSE:VOR) to Buy

Key Points

• Stifel Nicolaus has upgraded Vor Biopharma (NYSE:VOR) from a "hold" rating to a "buy" rating, with a target price of $55.00, indicating a potential upside of 75.83% from its previous close.
• Vor Biopharma's stock currently has an average rating of "Moderate Buy" from analysts, with an average target price of $113.83.
• Institutional investors hold a significant portion of the company's stock, with 97.29% ownership by institutional investors and hedge funds, reflecting strong confidence in the company's potential.

Vor Biopharma (NYSE:VOR - Get Free Report) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating in a note issued to investors on Wednesday, MarketBeat Ratings reports. The firm presently has a $55.00 price objective on the stock. Stifel Nicolaus' target price suggests a potential upside of 75.83% from the company's previous close.

VOR has been the subject of a number of other reports. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. HC Wainwright restated a "buy" rating and set a $60.00 price target on shares of Vor Biopharma in a report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Vor Biopharma has an average rating of "Moderate Buy" and an average target price of $113.83.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock opened at $31.28 on Wednesday. The business has a 50-day moving average of $39.70 and a 200-day moving average of $23.05. The company has a market capitalization of $198.13 million, a PE ratio of -18.96 and a beta of 2.05. Vor Biopharma has a 1-year low of $2.62 and a 1-year high of $65.80.

Insiders Place Their Bets

In related news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $1.54, for a total transaction of $688,808.12. Following the completion of the sale, the insider owned 32,781,209 shares of the company's stock, valued at approximately $50,483,061.86. The trade was a 1.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 756,918 shares of company stock valued at $12,573,293 over the last ninety days. 0.45% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of Vor Biopharma during the second quarter valued at about $66,000. Money Concepts Capital Corp grew its holdings in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma during the first quarter valued at about $100,000. Finally, Northern Trust Corp grew its holdings in shares of Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after buying an additional 44,252 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.